EGFR Composition for preventing or treating non small cell lung cancer harboring the EGFR mutations

• 1. 用三种完全人类单克隆抗EGFR抗体的组合治疗具有表皮生长因子受体（EGFR）的胞外结构域的突变的患者的方法 [P] . 中国专利： CN107889463A . 2018-04-06
• 2. 治疗非小细胞肺癌的EGFR T790M 抑制剂与EGFR 抑制剂的组合 [P] . 中国专利： CN105073116A . 2015-11-18
• 3. EGFR Composition for preventing or treating non small cell lung cancer harboring the EGFR mutations [P] . 韩国专利： KR102161720B1 . 2020-10-05

  机译： 用于预防或治疗具有EGFR突变的非小细胞肺癌的EGFR组合物

• 4. Composition for preventing or treating non small cell lung cancer harboring the EGFR mutations [P] . 韩国专利： KR1020200045666A . 2020.05.06
• 5. COMPOSITION FOR PREVENTING OR TREATING EGFR-MUTANT NON-SMALL CELL LUNG CANCER [P] . 美国专利： US2020121645A1 . 2020-04-23

  机译： 预防或治疗EGFR突变型非小细胞肺癌的组合物

• 1. EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation [J] . Yang Chen, Youyou Wang, Lujun Zhao, 癌症生物学与医学：英文版 . 2018,第001期
• 2. EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation [J] . Yang Chen, Youyou Wang, Lujun Zhao, 癌症生物学与医学：英文版 . 2018,第001期
• 3. EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation [J] . Yang Chen, Youyou Wang, Lujun Zhao, 癌症生物学与医学（英文版 ） . 2018,第001期
• 4. Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors [J] . WeiZ., AnT., WangZ., Thoracic cancer. . 2014,第2期
• 5. Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non‐small cell lung cancer when treated with EGFR‐tyrosine kinase inhibitors [J] . Guangying Zhu, Hua Bai, Jianchun Duan, Thoracic cancer. . 2014,第2期
• 6. Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors [J] . Imai Hisao, Yamada Yutaka, Sugiyama Tomohide, Chemotherapy: International Journal of Experimental and Clinical Chemotherapy . 2018,第3期
• 7. In Non-Small Cell Lung Cancer, Can Radiomic Features Predict EGFR Mutations? [C] . Jiayan Liu, Lin Liu, Yue Ma, IEEE International Conference on Mechatronics and Automation . 2019
• 8. Effects of TNFAIP8 knockdown on EGFR and IGF-1R signaling and cytotoxicities of targeted drugs in non-small cell lung cancer cells [D] . Day, Timothy Francis 2015
• 9. Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors [O] . Zhigang Wei, Tongtong An, Zhijie Wang, 2014
• 10. Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors [O] . Zhigang Wei, Tongtong An, Zhijie Wang, 2014

• 1. Efficacy of EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients Harboring Different Types of EGFR Mutations: A Retrospective Analysis [J] . Hua-li LIU ,Guang HAN ,Min PENG . 华中科技大学学报（医学）（英德文版） . 2017,第006期
• 2. Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation [J] . Saki Manabe ,Fumihiro Oshita ,Shuji Murakami . 癌症治疗（英文） . 2015,第15期
• 3. 吉林省非小细胞肺癌患者EGFR基因突变具有区域独特性 [C] . 李慧 ,吴春娇 ,柳影 . 第13届全国肺癌学术大会 . 2013
• 4. TP53基因突变对一代EGFR-TKIs治疗EGFR突变型晚期非小细胞肺癌临床疗效的影响 [A] . 秦康 . 2020